Activity Details

0.25 AMA PRA Category 1 Credits™/
MOC Points
0.25 Contact Hour(s)
Released: December 20, 2018
Expires: December 19, 2019
15 minutes to complete

Jointly Provided by

Target Audience

This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).

Learning Objectives

  • Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
  • Interpret the results of genomic testing accurately, including working effectively with genetic counselors
  • Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
  • Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families

Activity Description

This case-based webinar includes implications of genetic testing for treatment decisions, and reviews the safety and efficacy of FDA-approved PARP inhibitors for patients with metastatic or advanced breast cancer with germline BRCA mutations.

Statement of Educational Need

MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.


Joy Larsen Haidle, MS, CGC
Ruth M. O’Regan, MD
Associate Director, Clinical Research
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

The following faculty report that they have relevant financial relationships to disclose:
  • Ruth O’Regan, MD, has done contract research for Eisai, Novartis and Pfizer, Inc. Dr. O’Regan has served as an advisor for Genentech, Immunogenics, Lilly, MacroGenics, Novartis, Pfizer, Inc. and Puma.

Jennie Petruney, ANP
Nurse Practitioner
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

The following faculty report that they have no relevant financial relationships to disclose:
  • Jennie Petruney, ANP

MOC Reviewers

Theodore Bruno, MD
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut

The following faculty report that they have relevant financial relationships to disclose:
  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.

Patrick Thomas Grogan, MD, PhD
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin

The following faculty report that they have no relevant financial relationships to disclose:
  • Patrick Thomas Grogan, MD, PhD

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of TFF, ACCC and ONS. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Oncology Nursing Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Participants in PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Understanding and Applying PARP Inhibitor Data to Selection and Monitoring can earn a maximum of 0.25 contact hours of CNE upon the successful completion of this continuing education activity. No partial credit will be given. Participants must view sessions in their entirety and submit a completed evaluation within the specified time frame to receive CNE credit. NOTE: It is not required to complete all three parts of the series to claim your CNE certificate for one of the parts.


ILNA Information 
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. CNE sessions have been classified into the following ILNA categories for all certification renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON)  

  • Coordination of Care – 0.25 points
  • Diagnosis and Staging – 0.25 points
  • Treatment – 0.25 points

Method of Participation / How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.